Jason Shafrin

19PUBLICATIONS

28CO-AUTHORS

Haematological tumoursNaturopathyCancer therapy (excl. chemotherapy and radiation therapy)Econometric and statistical methodsEpidemiological modelling

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|Jul 14, 2026

Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.

|Feb 23, 2026

Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.

Karim El-Kersh, Nadine Zawadzki, Catelyn Coyle

|Jan 10, 2026

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Kyi-Sin Than, Jason Shafrin, Sanjana Muthukrishnan

|Nov 26, 2025

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States.

Jason Shafrin, Kejal Jadhav, Cheryl Warren

|Nov 26, 2025

Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe

|Jul 15, 2025

Two Approaches for Measuring Treatment Value Under Uncertainty: Estimating Insurance Value and Risk Preferences in Neurology.

Jason Shafrin, Kyi-Sin Than, Jacob Fajnor

Pageof 4

Frequent Collaborators

2 joint publications

Sanjana Muthukrishnan

Kyi-Sin Than

Suepattra G May

Caroline Huber

Meaghan Roach

Wade Aubry

Darius Lakdawalla

John M Kane

David Wei

Lauren M Zhao

Frequent Collaborators

2 joint publications

Sanjana Muthukrishnan

2 joint publications

Kyi-Sin Than

1 joint publications

Suepattra G May

1 joint publications

Caroline Huber